We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.27% | 39.90 | 40.005 | 39.49 | 39.97 | 4,916,752 | 22:16:55 |
From Jul 2019 to Jul 2024
By Chris Wack
Artelo Biosciences Inc. shares rose 8% to $2.11 after the company said it has been accepted into the first round of the Alderley Park Oncology Development Program, a U.K. national program designed to offer advice, guidance, and financial support to develop and progress innovative oncology projects.
The biopharmaceutical company said the program is funded by Innovate UK and Cancer Research UK and supported by major oncology-focused pharmaceutical companies including AstraZeneca, Johnson & Johnson, GlaxoSmithKline and Roche.
Artelo's application is focused on developing a pathway to a validated FABP5 biomarker.
The company said this acceptance could bring additional funding to its overall FABP5 inhibitor program, which has separately received nearly $8 million in support from the U.S. government and can allow its scientists to collaborate with leading UK research institutes and leading oncology pharmaceutical companies to develop a personalized medicine strategy for ART26.12.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 19, 2021 10:34 ET (14:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
